Central tenet of cancer cachexia therapy: Do patients with advanced cancer have exploitable anabolic potential?

American Journal of Clinical Nutrition

Volumn 98, Issue 4, 2013, Pages 1012-1019

  Prado, Carla M ^a   Sawyer, Michael B ^b   Ghosh, Sunita ^b   Lieffers, Jessica R ^b   Esfandiari, Nina ^b   Antoun, Sami ^c   Baracos, Vickie E ^b  

^a FLORIDA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT;

ADULT; ADVANCED CANCER; ARTICLE; BILE DUCT CARCINOMA; BIOSYNTHESIS; BODY COMPOSITION; CACHEXIA; CANCER PAIN; CANCER SURVIVAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIET THERAPY; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MUSCLE ATROPHY; MUSCLE METABOLISM; NAUSEA; OBSERVATIONAL STUDY; PANCREAS CANCER; QUANTITATIVE ANALYSIS; RISK FACTOR;

ADIPOSE TISSUE; AGED; BODY COMPOSITION; CACHEXIA; CHOLANGIOCARCINOMA; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUNG NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NEOPLASM STAGING; NEOPLASMS; PANCREATIC NEOPLASMS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84884840514     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.113.060228     Document Type: Article

References (29)

1. Smith KL, Tisdale MJ. Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia. Br J Cancer 1993;67:680-5. (Pubitemid 23101543)
2. Saini A, Faulkner S, Al-Shanti N, Stewart C. Powerful signals for weak muscles. Ageing Res Rev 2009;8:251-67.
3. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009;15:2920-6.
4. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008;9:629-35.
5. Lieffers JR, Bathe OF, Fassbender K, Winget M, Baracos VE. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer 2012;107:931-6.
6. Prado CMM, Mourtzakis M, Baracos V, Reiman T, Sawyer M, McCargar LJ. Overweight and obese patients with solid tumors may have sarcopenia, poor prognosis and early features of cachexia. Int J Body Compos Res 2010;8:7-15.
7. Peng PD, van Vledder MG, Tsai S, de Jong MC, Makary M, Ng J, Edil BH, Wolfgang CL, Schulick RD, Choti MA, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB(Oxford) 2011;13:439-46.
8. Deutz NE, Safar A, Schutzler S, Memelink R, Ferrando A, Spencer H, van Helvoort A, Wolfe RR. Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin Nutr 2011;30:759-68.
9. Winter A, MacAdams J, Chevalier S. Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. Clin Nutr 2012;31:765-73.
10. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009;15:6973-9.
11. Lieffers JR, Mourtzakis M, Hall KD, McCargar LJ, Prado CM, Baracos VE. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to wholebody energy demands. Am J Clin Nutr 2009;89:1173-9.
12. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489-95.
13. Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 2010;91:1133S-7S.
14. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, LyonsW, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 1998;85:115-22. (Pubitemid 28334913)
15. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998;351:871-5. (Pubitemid 28121176)
16. Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 2009;3:269-75.
17. Thibault R, Genton L, Pichard C. Body composition: why, when and for who? Clin Nutr 2012;31:435-47.
18. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, Heymsfield SB, Heshka S. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 2004;97:2333-8. (Pubitemid 39552474)
19. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008;33: 997-1006.
20. Frontera WR, Meredith CN, O'Reilly KP, Knuttgen HG, Evans WJ. Strength conditioning in older men: skeletal muscle hypertrophy and improved function. J Appl Physiol 1988;64:1038-44. (Pubitemid 18088522)
21. Prado CM, Bekaii-Saab T, Doyle LA, Shrestha S, Ghosh S, Baracos VE, Sawyer MB. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer 2012;106:1583-6.
22. Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, Murray GD. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006;24:3401-7. (Pubitemid 46638896)
23. Fearon KC, Von Meyenfeldt MF, Moses AG, Van Geenen R, Roy A, Gouma DJ, Giacosa A, Van Gossum A, Bauer J, Barber MD, et al. Effect of a protein and energy dense N23 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003;52:1479-86. (Pubitemid 37176729)
24. Jatoi A, Dakhil SR, Nguyen PL, Sloan JA, Kugler JW, Rowland KM Jr, Soori GS, Wender DB, Fitch TR, Novotny PJ, et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer 2007;110:1396-403. (Pubitemid 47435614)
25. Jatoi A, Ritter HL, Dueck A, Nguyen PL, Nikcevich DA, Luyun RF, Mattar BI, Loprinzi CL. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer 2010;68:234-9.
26. Wiedenmann B, Malfertheiner P, Friess H, Ritch P, Arseneau J, Mantovani G, Caprioni F, Van Cutsem E, Richel D, DeWitte M, et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008;6:18-25. (Pubitemid 351227865)
27. Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008;44:1124-32.
28. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 2013;10: 90-9.
29. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol 2010;28: 1054-60.